Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | RET C634R RET Y806F |
Therapy | Vandetanib |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET C634R RET Y806F | Advanced Solid Tumor | predicted - sensitive | Vandetanib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806F in culture demonstrated inhibition of Ret phosphorylation and activity in kinase assays when treated with Caprelsa (vandetanib) (PMID: 19029224). | 19029224 |
PubMed Id | Reference Title | Details |
---|---|---|
(19029224) | Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474. | Full reference... |